Study S000872

RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

ClinicalTrials.gov record

Registration

Registration: NCT06987513
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 100
Start: 2025-05-15
Primary completion: 2026-07-30
Lead sponsor: Altimmune, Inc.
Conditions: Alcohol Use Disorder (AUD)
Interventions: DRUG:Pemvidutide; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Change from baseline in the average number of heavy drinking days per week [Baseline to Weeks 21-24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.